Clinical

US adults who survived a COVID-19 infection are more likely than individuals who were not infected with COVID-19 to develop incident conditions attributable to the virus.

Investigators in Spain evaluated symptoms and comorbidities associated with eosinophilic esophagitis.

The researchers found that extramedullary disease at diagnosis was significantly more common in patients with bone marrow fibrosis.

Data to be presented next week during the American Society of Clinical Oncology Annual Meeting show that for every 10% increase in public welfare spending, there was a 4.55% narrowing of the 5-year overall survival (OS) disparity between Black and White patients with cancer.

As biosimilar competition heats up in the United States, payers have more tools at their disposal to manage these agents.

Key opinion leaders share their perspectives on utilization management strategies in treatment of women’s health.

The panel deliberates appropriate surgical intervention in women with uterine fibroids or endometriosis.

A survey of blood and bone marrow transplant patients found that many who fit current criteria for ocular graft-versus-host disease have not been diagnosed.

The governor of Oklahoma signs the nation's most restrictive abortion ban; vaccination against COVID-19 may not prevent long COVID-19; West Virginia reaches tentative settlement with opioid manufacturers.

Steven Yeh, MD, professor of ophthalmology at the Truhlsen Eye Institute at the University of Nebraska Medical Center, talks about what he sees in the future of suprachoroidal administration and other unmet needs in ophthalmology.

Miruna Sasu, PhD, MBA, president and CEO of COTA Healthcare, discusses 3 ways in which the FDA can provide, and has provided, assistance on the capture of real-word data (RWD) in electronic medical records.

The findings could lead to new insights into how type 1 diabetes develops.

A longitudinal cohort study found that mild albuminuria was associated with cognitive decline, worse baseline cognitive function, and increased risk of incident cognitive impairment and dementia.

On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.

There are an increasing number of targeted therapies in oncology, but challenges around biomarker testing and treatment selection remain.

Abstracts presented at Digestive Disease Week 2022 showed that RBX2660, an investigational microbiota-based drug, was more likely to reduce the recurrence of Clostridioides difficile infection (CDI) compared with placebo.

Dr Slipczuk offers strategies for sharing information and guiding appropriate ASCVD treatment both within and outside closed health systems.

Leandro N. Slipczuk, MD, PhD, details his organization’s effort to support uptake of PCSK9 inhibitors in the inpatient setting.

During a State-of-the-Art Lecture at Digestive Disease Week 2022, Jessica L. Mellinger, MD, MSc, explained how the COVID-19 pandemic has driven increases in rates of alcohol use and associated liver disease, as well as what can be done at the clinic, societal, and policy levels to address these trends.

A recent study found that patients with chronic kidney disease (CKD) had a poor prognosis based on glomerular filtration rate (GFR), ankle-brachial index (ABI), and high systolic blood pressure in a 16-week exercise program.

Medical oncologist Jeffrey S. Weber, MD, PhD, spoke with The American Journal of Managed Care® (AJMC®) about how treatment options have improved for more advanced melanoma cases and the role that genetic mutations play in choosing therapy.

Real-world treatment of diabetic kidney disease in the United States, based on national-level health care claims and electronic health records data, is inconsistent with the current guidelines.

Evidence shows that weight loss achieved through bariatric and endoscopic surgery can help treat and reverse nonalcoholic fatty liver disease (NAFLD), but optimal procedure selection and timing vary by patient factors, according to speakers at Digestive Disease Week 2022.

A pair of posters presented at Digestive Disease Week 2022 showed the efficacy of an investigational biotherapeutic in preventing Clostridioides difficile infection recurrence and restoring the microbiome.

A recent study identified TIGIT as a marker of chimeric antigen receptor (CAR) T-cell exhaustion and found it to improve CAR T-cell therapy efficacy in preclinical models.